Search NLS News

A Memorandum of Understanding (MoU) was signed between the University of Oslo and the Karolinska Institute during a visit by the Norwegian Crown Prince Couple and a Norwegian industry delegation in Stockholm on 2 May. “Norway and Sweden must work together towards making precision medicine a standard for all cancer patients,” says Ketil Widerberg, general […]

Bio-Me today has become part of the Medicen Microbiome Drug Metabolism working group, an international initiative by leading academic, pharma and institutions to address the need for better understanding of drug-microbiome interactions. The working group initiated by the Medicen Paris Region cluster comprises a network of more than 30 academic groups, biotech companies, CROs and associations, and […]

The company announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), has unanimously adopted a positive opinion recommending a full marketing authorization approval (MAA) of Pepaxti in EU. The European Commission (EC) will make a legally binding decision based on the EMA recommendation within 60 days. Once granted by […]

The life science industry organization SwedenBIO pushed for stronger global collaborations on antimicrobial resistance (AMR) at the BIO International Convention in San Diego, U.S., earlier in June. The organization also strengthened the Swedish participation in the International Council of Biotech Associations (ICBA) by taking over the chair on AMR issues. The AMR threat may not […]

Immunicum announces corporate rebranding and name change to Mendus AB. The rebranding reflects an advancing pipeline in next generation cancer immunotherapies, upcoming manufacturing expansion, and long-term corporate aspirations, states the company. “The name Mendus captures our continued commitment to develop therapies that delay or reduce cases of cancer recurrence, while preserving the quality of life […]

The two companies have announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders. Echosens and Novo Nordisk will collaborate to support additional clinical validation, generation of real-world evidence and adoption of non-invasive diagnostic tests for NASH and work together to […]

AlzeCure Pharma has announced that the first patient has been included in a Phase II clinical trial with ACD440, a non-opioid drug candidate in the Painless platform which is being developed for peripheral neuropathic pain. This follows the recent approvals from regulatory authorities to begin the study. “This is a big step for both the […]

Investors in the private placement include OnDosis founders AstraZeneca and Martin Olovsson and major shareholders Aeternum Capital, DIG Investment and Rydgruppen. The private placement enables acceleration of new projects in collaboration with an unnamed license partner as well as the building of the digital platform for the company to develop and introduce closed loop disease […]

Under the agreement, Zealand will contribute its expertise in peptide drug discovery to Iktos’ generative modelling technologies and expertise in machine learning and AI. “We are very pleased to join forces with Zealand Pharma and leverage their deep know-how in peptide therapeutics with our state-of-the-art existing technology assets to peptide drug discovery,” says Yann Gaston-Mathé, […]

NorthX Biologics is expanding into cell therapy manufacturing at its existing GMP-facility, as well as in premises at the Karolinska University Hospital campus in Stockholm. This initiative is part of NorthX’s Innovation Hub, an Innovation Track designed to provide development and GMP-manufacturing services to the next generation of drug development companies and innovative research groups […]